Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Carboplatin and Doxorubicin in Treatment of Pediatric Osteosarcoma: A 9-year Single Institute Experience in the Northern Region of Thailand

  • Published : 2013.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Osteosarcoma is the most common primary bone tumor in childhood and adolescence. Carboplatin, a platinum-derived agent, is used as neoadjuvant chemotherapy for pediatric osteosarcoma because of its anti-tumor activity and had low toxicity as compared to cisplatin. Objective: To determine demographic data, prognostic factors and outcome of childhood osteosarcoma treated with a carboplatin-based chemotherapeutic protocol at Chiang Mai University. Method: A retrospective analysis was conducted on 34 osteosarcoma patients aged less than 18 years and treated between 2003 and 2011. Results: Overall limb-salvage and amputation rates were 23.5% and 70.6%, respectively. With the mean follow-up time of 29.5 months (1.5-108.9), the Kaplan-Meier analysis for 3-year disease-free survival (DFS) and 3-year overall survival (OS) were $20.2{\pm}7.7%$ and $47.1{\pm}9.5%$ respectively. Patients who had initial pulmonary metastasis were at significantly greater risk for developing recurrence (p=0.02, OR=7; 1.2-40.1) and had a tendency to have lower 3-year OS compared to those without initial pulmonary metastasis ($28.1{\pm}13%$, $63.1{\pm}12.3%$, respectively, p=0.202). On univariate analysis, age at diagnosis >14 years and patients who were declined surgery were significantly associated with lower 3-year OS (p=0.008 and <0.05, respectively). However, age at diagnosis, sex, tumor size and histological subtypes were not found to significantly affect recurrence or survival. Conclusions: In our study, the survival rate was far lower than those reported from developed countries. These might indicate the ineffectiveness of carboplatin in combination with doxorubicin as frontline treatment of pediatric osteosarcoma, especially in those with initial pulmonary metastasis. Refinement in risk and treatment stratification and dose intensification for pediatric osteosarcoma constitutes a future challenge to improve outcomes, especially in metastatic patients who may need a more intensive regimen.

Keywords

References

  1. Bacci G, Briccoli A, Ferrari S, et al (2001). Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer, 37, 2030-9. https://doi.org/10.1016/S0959-8049(01)00229-5
  2. Bacci G, Briccoli A, Longhi A, et al (2005). Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol, 44, 748-55. https://doi.org/10.1080/02841860500327503
  3. Bergman PJ, MacEwen EG, Kurzman ID, et al (1996). Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med, 10, 76-81. https://doi.org/10.1111/j.1939-1676.1996.tb02031.x
  4. Bramwell VH, Burgers M, Sneath R, et al (1992). A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol, 10, 1579-91.
  5. Cortes EP, Holland JF, Wang JJ, et al (1972). Doxorubicin in disseminated osteosarcoma. JAMA, 221, 1132-8. https://doi.org/10.1001/jama.1972.03200230020005
  6. Cortes EP, Holland JF, Wang JJ, et al (1974). Amputation and adriamycin in primary osteosarcoma. N Engl J Med, 291, 998-1000. https://doi.org/10.1056/NEJM197411072911903
  7. Coventry MB, Dahlin DC (1957). Osteogenic sarcoma; a critical analysis of 430 cases. J Bone Joint Surg Am, 39, 57-8.
  8. Crnalic S, Bergstrom P, Lofvenberg R, et al (1996). Antagonistic effect of amphotericin B on carboplatin antitumor activity in human osteosarcoma xenografts. Anticancer Drugs, 7, 489-92. https://doi.org/10.1097/00001813-199606000-00015
  9. Dahlin DC, Coventry MB (1967). Osteogenic sarcoma. A study of six hundred cases. J Bone Joint Surg Am, 49, 101-10.
  10. Dahlin DC (1978). Osteosarcoma of bone and a consideration of prognostic variables. Cancer Treat Rep, 62, 189-92.
  11. Daw NC, Neel MD, Rao BN, et al (2011). Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 Trial. Cancer, 117, 2770-8. https://doi.org/10.1002/cncr.25715
  12. Delepine N, Delepine G, Bacci G, et al (1996). Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature. Cancer, 78, 2127-35. https://doi.org/10.1002/(SICI)1097-0142(19961115)78:10<2127::AID-CNCR13>3.0.CO;2-0
  13. Eilber F, Giuliano A, Eckardt J, et al (1987). Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol, 5, 21-6.
  14. Ferguson WS, Harris MB, Goorin AM, et al (2001). Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial. J Pediatr Hematol Oncol, 23, 340-8. https://doi.org/10.1097/00043426-200108000-00004
  15. Ferrari S, Bertoni F, Mercuri M, et al (2001). Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol, 12, 1145-50. https://doi.org/10.1023/A:1011636912674
  16. Fletcher CD (2006). The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology, 48, 3-12. https://doi.org/10.1111/j.1365-2559.2005.02284.x
  17. Gaffney R, Unni KK, Sim FH, et al (2006). Follow-up study of long-term survivors of osteosarcoma in the prechemotherapy era. Hum Pathol, 37, 1009-14. https://doi.org/10.1016/j.humpath.2006.02.022
  18. Hagleitner MM, Hoogerbrugge PM, van der Graaf WT, et al (2011). Age as prognostic factor in patients with osteosarcoma. Bone, 49, 1173-7. https://doi.org/10.1016/j.bone.2011.08.014
  19. Hudson M, Jaffe MR, Jaffe N, et al (1990). Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol, 8, 1988-97.
  20. Jaffe N, Paed D, Farber S, et al (1973). Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer, 31, 1367-73. https://doi.org/10.1002/1097-0142(197306)31:6<1367::AID-CNCR2820310611>3.0.CO;2-6
  21. Lee JA, Kim MS, Kim DH, et al (2009). Risk stratification based on the clinical factors at diagnosis is closely related to the survival of localized osteosarcoma. Pediatr Blood Cancer, 52, 340-5. https://doi.org/10.1002/pbc.21843
  22. Lewis IJ, Weeden S, Machin D, et al (2000). Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup. J Clin Oncol, 18, 4028-37.
  23. Lewis IJ, Nooij MA, Whelan J, et al (2007). Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst, 99, 112-28. https://doi.org/10.1093/jnci/djk015
  24. Link MP, Goorin AM, Miser AW, et al (1986). The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med, 314, 1600-6. https://doi.org/10.1056/NEJM198606193142502
  25. Lokich J, Anderson N (1998). Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol, 9, 13-21.
  26. Mankin HJ, Hornicek FJ, Rosenberg AE, et al (2004). Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res, 429, 286-91. https://doi.org/10.1097/01.blo.0000145991.65770.e6
  27. Meyer WH, Pratt CB, Poquette CA, et al (2001). Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol, 19, 171-82.
  28. Mirabello L, Troisi RJ, Savage SA (2009). Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer, 115, 1531-43. https://doi.org/10.1002/cncr.24121
  29. Mirabello L, Troisi RJ, Savage SA (2009). International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer, 125, 229-34. https://doi.org/10.1002/ijc.24320
  30. Petrilli AS, Kechichian R, Broniscer A, et al (1999). Activity of intraarterial carboplatin as a single agent in the treatment of newly diagnosed extremity osteosarcoma. Med Pediatr Oncol, 33, 71-5. https://doi.org/10.1002/(SICI)1096-911X(199908)33:2<71::AID-MPO2>3.0.CO;2-T
  31. Pratt CB, Howarth C, Ransom JL, et al (1980). High-dose methotrexate used alone and in combination for measurable primary or metastatic osteosarcoma. Cancer Treat Rep, 64, 11-20.
  32. Robson H, Meyer S, Shalet SM, et al (2002). Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines. Med Pediatr Oncol, 39, 573-80. https://doi.org/10.1002/mpo.10076
  33. Saeter G, Alvegard TA, Elomaa I, et al (1991). Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol, 9, 1766-75.
  34. Smith MA, Seibel NL, Altekruse SF, et al (2010). Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol, 28, 2625-34. https://doi.org/10.1200/JCO.2009.27.0421
  35. Stiller CA, Craft AW, Corazziari I (2001). Survival of children with bone sarcoma in Europe since 1978: results from the EUROCARE study. Eur J Cancer, 37, 760-6. https://doi.org/10.1016/S0959-8049(01)00004-1
  36. Stiller CA, Bielack SS, Jundt G, et al (2006). Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer, 42, 2124-35. https://doi.org/10.1016/j.ejca.2006.05.015
  37. Souhami RL, Craft AW, Van der Eijken JW, et al (1997). Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet, 350, 911-7. https://doi.org/10.1016/S0140-6736(97)02307-6
  38. Van Winkle P, Angiolillo A, Krailo M, et al (2005). Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer, 44, 338-47. https://doi.org/10.1002/pbc.20227
  39. Wiangnon S, Veerakul G, Nuchprayoon I, et al (2011). Childhood cancer incidence and survival 2003-2005, Thailand: study from the Thai Pediatric Oncology Group. Asian Pac J Cancer Prev, 12, 2215-20.
  40. Wiromrat P, Jetsrisuparb A, Komvilaisak P, et al (2012). Incidence and survival rates among pediatric osteogenic sarcoma cases in Khon Kaen, Thailand, 1985-2010. Asian Pac J Cancer Prev, 13, 4281-4. https://doi.org/10.7314/APJCP.2012.13.9.4281

Cited by

  1. The Synergistic Anticancer Effect of Artesunate Combined with Allicin in Osteosarcoma Cell Line in Vitro and in Vivo vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4615
  2. Comparative Outcome of Thai Pediatric Osteosarcoma Treated with Two Protocols: the Role of High-Dose Methotrexate (HDMTX) in a Single Institute Experience vol.15, pp.22, 2014, https://doi.org/10.7314/APJCP.2014.15.22.9823
  3. Comparison of Carboplatin and Doxorubicin-Based Chemotherapy Protocols in 470 Dogs after Amputation for Treatment of Appendicular Osteosarcoma vol.28, pp.2, 2014, https://doi.org/10.1111/jvim.12313